How Marstacimab Targets TFPI to Restore Coagulation

Marstacimab restores hemostasis by inhibiting the binding between tissue factor pathway inhibitor (TFPI) and Factor Xa (FXa), thereby relieving a natural brake on coagulation that is disproportionately damaging in hemophilia patients. Rather than replacing the missing clotting factor directly, marstacimab rebalances the coagulation cascade from the inhibitory side—a fundamentally different approach from factor concentrates and a mechanistically distinct one from the two most prominent non-factor alternatives already on the market.

TFPI is an endogenous anticoagulant that normally limits the initial burst of thrombin generation triggered by the tissue factor/Factor VIIa complex. In healthy individuals this regulation is balanced; in patients with hemophilia A or B, where Factor VIII or Factor IX is deficient or absent, the same TFPI-mediated inhibition becomes an additional obstacle to achieving adequate clot formation. By blocking TFPI’s interaction with FXa, marstacimab effectively amplifies the residual coagulation capacity available to hemophilia patients, regardless of which clotting factor they lack.

This mechanism has a clinically significant implication: because TFPI inhibition acts downstream of both Factor VIII and Factor IX, a single molecule can theoretically address both hemophilia A and hemophilia B. This is in contrast to emicizumab, which mimics Factor VIII cofactor function and is therefore specific to hemophilia A. The breadth of marstacimab’s potential patient population is one of the most important strategic differentiators visible in Pfizer’s patent filings, as discussed by WIPO-registered international applications covering both disease subtypes simultaneously.

The Subcutaneous Dosing Strategy and Patent Coverage

Marstacimab is administered subcutaneously at a loading dose of 300 mg followed by weekly maintenance doses of 150 mg—a regimen that is consistent across Pfizer’s patent filings for both hemophilia A and B patients, and for those both with and without inhibitors to clotting factors. This standardised dosing architecture simplifies clinical development and, if approved, would streamline prescribing across a heterogeneous patient population.

Pfizer’s patent documents also disclose methods for monitoring treatment efficacy by tracking plasma anti-Xa activity, providing a pharmacodynamic marker that can be used to confirm that TFPI inhibition is achieving the intended effect and to adjust therapy if needed. This monitoring strategy is codified in patents covering both the inhibitor and non-inhibitor populations, suggesting Pfizer intends it as a standard component of the therapeutic protocol.

Beyond weekly dosing, Pfizer has also filed patents covering bi-weekly dosing schedules (WO2024084394A1), indicating that the company is exploring less frequent administration that could improve patient convenience and adherence—a critical competitive factor in a market where monthly subcutaneous injection (fitusiran) and subcutaneous every-one-to-four-weeks dosing (emicizumab) are already established alternatives. The dosing flexibility patent filings suggest Pfizer is preparing for a Phase III programme that may test multiple schedules.

Pfizer’s Global Patent Fortress Around Marstacimab

Pfizer has constructed one of the most geographically comprehensive patent portfolios in the hemophilia non-factor space, with marstacimab filings spanning at least 12 jurisdictions: the United States, European Patent Office (EP), China (CN), Japan (JP), South Korea (KR), Australia (AU), Canada (CA), Mexico (MX), Israel (IL), and others. The portfolio is structured in three strategic layers—antibody composition, pharmaceutical formulation, and clinical method of use—providing overlapping protection that will be difficult for competitors to design around.

The composition patents (WO2014193829A2, US10100117B2, US10556947B2, US10544210B2, US11149088B2, US11572416B2) cover the anti-TFPI antibody itself, including variants that inhibit TFPI–FXa binding. The formulation patents (WO2018191297A1, EP3458480B1, US10738128B2, US11203645B2) protect stable aqueous pharmaceutical compositions suitable for subcutaneous delivery. The method-of-use patents are split by patient subpopulation: one family covers hemophilia A and B without inhibitors (WO2021038341A1, US11629196B2), and a separate family covers the inhibitor population (WO2023073474A1, WO2023073473A1, US11572415B2), with a combined filing (WO2024084394A1) consolidating coverage across both groups and adding bi-weekly dosing claims.

“Pfizer’s marstacimab portfolio covers both hemophilia A and B—with and without inhibitors—across at least 12 jurisdictions, from composition patents filed as early as 2014 to method-of-use patents as recent as 2024.”

The temporal spread of the portfolio is equally notable. The earliest anti-TFPI antibody composition patents trace back to WO2014193829A2 (published December 2014), while the most recent dosing method filings extend to WO2024084394A1 (April 2024). This decade-long filing cadence indicates sustained R&D investment and a deliberate strategy to extend effective market exclusivity through successive innovation claims—a pattern that EPO patent analysts have identified as characteristic of large-molecule biologics programmes in rare disease indications.

Non-Factor Replacement Therapy: Three Mechanisms, One Market

The non-factor replacement therapy space for hemophilia is defined by three distinct molecular mechanisms competing for the same patient population: emicizumab (bispecific antibody mimicking Factor VIII cofactor function, approved for hemophilia A), fitusiran (RNAi therapy silencing antithrombin, approved for hemophilia A and B), and marstacimab (anti-TFPI antibody, in Phase III for hemophilia A and B). Each targets a different node in the coagulation network, and each carries a different set of clinical trade-offs.

Emicizumab, marketed as Hemlibra by Roche/Genentech and approved by the FDA in 2017, established the non-factor category and remains the dominant player. Its once-weekly, bi-weekly, or monthly subcutaneous dosing and strong clinical data in both inhibitor and non-inhibitor hemophilia A patients have made it the standard of care in that subpopulation. However, its Factor VIII-mimetic mechanism means it has no activity in hemophilia B—a gap that marstacimab and fitusiran are both designed to fill.

Fitusiran (Alhemo, Sanofi) uses RNA interference to silence antithrombin, a natural anticoagulant, thereby rebalancing coagulation. Like marstacimab, it is applicable to both hemophilia A and B and to patients with inhibitors. Its monthly subcutaneous dosing is a potential adherence advantage over weekly regimens. However, the RNAi mechanism introduces distinct safety considerations around thrombotic risk that have shaped its clinical development and labelling. Bayer has also entered the TFPI space with bispecific antibody approaches (US20230017918A1), suggesting the anti-TFPI target is attracting broader competitive interest beyond Pfizer alone.

What the Patent Record Signals About Pfizer’s Clinical Strategy

Reading the marstacimab patent record as a strategic document reveals several deliberate choices about how Pfizer intends to position the drug in Phase III and beyond. The separation of inhibitor and non-inhibitor populations into distinct patent families—with separate filings for WO2021038341A1 (non-inhibitor) and WO2023073474A1 (inhibitor)—mirrors the typical Phase III trial design, where these populations are studied in parallel but separate arms. This parallel development strategy maximises the addressable patient population at launch and provides regulatory flexibility.

The 2024 consolidated filing (WO2024084394A1) covering both populations and adding bi-weekly dosing claims suggests that Pfizer may be preparing to seek approval for a flexible dosing label—potentially every one to two weeks—which would bring marstacimab’s convenience profile closer to emicizumab’s most popular bi-weekly schedule. If successful, this would remove one of the key practical advantages currently held by the market leader.

The monitoring strategy—using plasma anti-Xa activity as a pharmacodynamic marker—is also patent-protected, which could create a proprietary companion monitoring protocol. According to standards published by ISTH (International Society on Thrombosis and Haemostasis), anti-Xa assays are well-established in clinical practice, but their specific application to TFPI inhibitor monitoring is novel and could differentiate the marstacimab prescribing experience from competitors that do not have an equivalent pharmacodynamic monitoring anchor.

For drug intelligence professionals tracking the hemophilia pipeline, the marstacimab patent record provides several actionable signals. First, the breadth of jurisdictional coverage—spanning major markets in North America, Europe, and Asia-Pacific—indicates Pfizer is preparing for a global launch, not a phased regional rollout. Second, the layered IP structure across composition, formulation, and method-of-use creates a barrier that generic and biosimilar entrants will face for many years post-approval. Third, the explicit patent coverage of both inhibitor and non-inhibitor populations signals that Pfizer intends to compete across the full hemophilia treatment landscape, not just in a niche segment. Tracking these filings through platforms like PatSnap’s innovation intelligence platform allows R&D teams to anticipate competitive moves before they surface in clinical trial registries or regulatory filings.